Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | DRD1 | P21728 | 2/20 | 0.32 |
| ▸ | DRD4 | P21917 | 2/20 | 0.32 |
| ▸ | DRD5 | P21918 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5651285 | 0.99 | HTR6 (0.58) | HTR6MTNR1AHTR2CDRD2DRD1 | |
| SCHEMBL5373922 | 0.86 | HTR6 (0.41) | HTR6MTNR1ADRD2DRD1DRD4 | |
| Hydrochloric Acid SCHEMBL5373921 | 0.85 | HTR6 (0.40) | HTR6MTNR1ADRD2DRD1DRD4 | |
| SCHEMBL5369725 | 0.79 | MTNR1A (0.48) | HTR6MTNR1A | |
| SCHEMBL5372049 | 0.78 | HTR6 (0.85) | HTR6DRD2 | |
| SCHEMBL5375353 | 0.76 | HTR6 (0.59) | HTR6 | |
| SCHEMBL5371232 | 0.76 | HTR6 (0.71) | HTR6DRD2 | |
| SCHEMBL5383569 | 0.75 | HTR6 (0.79) | HTR6DRD2 | |
| Hydrochloric Acid SCHEMBL5371228 | 0.75 | HTR6 (0.70) | HTR6DRD2 | |
| SCHEMBL5770874 | 0.75 | HTR6 (0.70) | HTR6HTR2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377580-B1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2006-09-27 | — | — | EP | claimed |
| US-20040102481-A1 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor | FILLA SANDRA ANN (US) | 2004-05-27 | — | — | US | claimed |
| US-20070135484-A1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | FILLA SANDRA A | 2007-06-14 | — | — | US | disclosed |
| US-20070135484-A1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | FILLA SANDRA A | 2007-06-14 | — | — | US | disclosed |
| US-20070135484-A1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | FILLA SANDRA A | 2007-06-14 | — | — | US | disclosed |
| US-7230011-B2 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5ht6 receptor | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1377580-B1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20040102481-A1 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor | FILLA SANDRA ANN (US) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102481-A1 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor | HTR6, HTR5A, TPH1 | HTR6 1/4885MTNR1A 55/4885HTR2C 16/4885 |
| US-20070135484-A1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR5A, HTR7 | HTR6 1/4885MTNR1A 76/4885HTR2C 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.